{"id":"piperacillin-tazobactam-amoxicillin-clavulanic-acid","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Piperacillin/Tazobactam and Amoxicillin/Clavulanic acid work by inhibiting the synthesis of the bacterial cell wall, ultimately leading to cell lysis and death. This mechanism is effective against a wide range of Gram-positive and Gram-negative bacteria. The addition of Tazobactam and Clavulanic acid provides protection against beta-lactamase degradation, allowing the antibiotics to remain effective against bacteria that produce these enzymes.","oneSentence":"Piperacillin/Tazobactam is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, while Amoxicillin/Clavulanic acid is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis and is protected from beta-lactamase degradation by Clavulanic acid.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:19.492Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia"},{"name":"Treatment of skin and soft tissue infections"}]},"trialDetails":[{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":"Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam","enrollment":300},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":"Administration of Antibiotics in Intensive Care Units","enrollment":98},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07082465","phase":"","title":"Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-08-01","conditions":"Drug Resistance, Bacterial, Bacteremia","enrollment":108000},{"nctId":"NCT06929702","phase":"PHASE4","title":"Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-04-22","conditions":"Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem","enrollment":58},{"nctId":"NCT04803422","phase":"NA","title":"Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2021-04-01","conditions":"Complicated Appendicitis","enrollment":3193},{"nctId":"NCT05753735","phase":"PHASE2","title":"eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-01-18","conditions":"Pancreatic Fistula","enrollment":3},{"nctId":"NCT04436991","phase":"","title":"Antibiotic Dosing in Geriatric Patients At the Emergency Department","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2018-01-03","conditions":"Elderly Infection, Frailty, Frail Elderly Syndrome","enrollment":180},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05724628","phase":"PHASE1","title":"Non-operative vs. Operative Management of Acute Appendicitis in Vulnerable Patient Populations","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-10","conditions":"Acute Appendicitis","enrollment":""},{"nctId":"NCT03897582","phase":"","title":"Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study","status":"RECRUITING","sponsor":"Centre Hospitalier de Valenciennes","startDate":"2019-02-22","conditions":"Beta-lactam, Continuous Renal Replacement Therapy, Pneumonia","enrollment":65},{"nctId":"NCT03909698","phase":"","title":"Antibiotic Dosing in Patients on Intermittent Hemodialysis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-09-15","conditions":"Kidney Failure, Chronic, Antibiotics, Hemodialysis","enrollment":150},{"nctId":"NCT04748120","phase":"NA","title":"Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-12-28","conditions":"Covid19, Appendicitis, Cholecystitis, Acute","enrollment":2},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03583749","phase":"","title":"Pharmacokinetics and Safety of Antimicrobial Agents Administered by Subcutaneous Route in Patients AGEd Over 65 Years","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2019-08-07","conditions":"Antimicrobials, Subcutaneous Injection, Antibiotic","enrollment":150},{"nctId":"NCT02795949","phase":"PHASE3","title":"Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2016-10","conditions":"Enterobacteriaceae Infections","enrollment":344},{"nctId":"NCT03080103","phase":"","title":"Appendectomy Versus Conservative Treatment for Uncomplicated Acute Appendicitis","status":"COMPLETED","sponsor":"Mauro Podda","startDate":"2017-06-01","conditions":"Acute Appendicitis, Appendicitis Recurrent, Appendectomy","enrollment":300},{"nctId":"NCT01951768","phase":"PHASE4","title":"Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2013-09","conditions":"Diabetic Foot Ulcer","enrollment":88},{"nctId":"NCT02189668","phase":"NA","title":"Non-operative Management of Pediatric Appendicitis With an Appendicoltih","status":"TERMINATED","sponsor":"Peter Minneci","startDate":"2014-07","conditions":"Appendicitis","enrollment":14},{"nctId":"NCT03435900","phase":"PHASE2","title":"Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated Appendicitis","status":"COMPLETED","sponsor":"Herlev Hospital","startDate":"2018-02-14","conditions":"Appendicitis Perforated","enrollment":13},{"nctId":"NCT02795793","phase":"NA","title":"Non-operative Management for Appendicitis in Children","status":"UNKNOWN","sponsor":"Sydney Children's Hospitals Network","startDate":"2016-05","conditions":"Acute Focal Appendicitis, Appendicitis","enrollment":226},{"nctId":"NCT01975493","phase":"","title":"Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2013-11","conditions":"Paediatric Antimicrobial Pharmacokinetics","enrollment":428},{"nctId":"NCT03410771","phase":"","title":"Bioelectrical Impedance Analysis as a Bedside Tool to Estimate Volume of Distribution of Hydrophilic Antimicrobials in Critically Ill Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-10-01","conditions":"Electric Impedance, Pharmacokinetics, Capillary Leak Syndrome","enrollment":68},{"nctId":"NCT03120663","phase":"","title":"Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-11-30","conditions":"Surgery","enrollment":120},{"nctId":"NCT01697059","phase":"NA","title":"Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis","status":"COMPLETED","sponsor":"Rhode Island Hospital","startDate":"2012-09","conditions":"Acute Appendicitis","enrollment":73},{"nctId":"NCT00402727","phase":"PHASE3","title":"Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-09","conditions":"Abscess, Wound Infection, Diabetic Foot","enrollment":813},{"nctId":"NCT01450241","phase":"NA","title":"Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia","status":"WITHDRAWN","sponsor":"Rabin Medical Center","startDate":"2012-01","conditions":"Febrile Neutropenia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":292,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid","genericName":"Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piperacillin/Tazobactam is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, while Amoxicillin/Clavulanic acid is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis and is protected from beta-lactamase degradation by Clavulanic acid. Used for Treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia, Treatment of skin and soft tissue infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}